CannEpil® is a phytocannabinoid derived IMP, designed to treat Drug Resistant Epilepsy with a high CBD, low THC formula. The Phase IIb clinical trial for CannEpil® has regulatory approval at the Schneider Children’s Medical Hospital in Israel and will focus on the safety and efficacy of CannEpil® as an add-on treatment for children and adolescents with treatment resistant epilepsy, also known as Refractory Epilepsy. This randomised placebo-controlled Phase IIb trial is targeting recruitment of more than 100 patients.
The agreement with AMC follows on from CannEpil® being added to the Primary Care Reimbursement Service in the Republic of Ireland (see announcement 14 June 2021), making it free of charge for Irish patients prescribed the treatment under the Medical Cannabis Access Program.
Approximately 50 million people worldwide suffer from epilepsy, with approximately 33% of adults, and 20-25% of children, suffering from Refractory Epilepsy (or Drug Resistant Epilepsy), which cannot be controlled with traditional anti-seizure medication, highlighting the size of the market for CannEpil®.